Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Completed · Phase 1

Conditions studied: Non-small Cell Lung Cancer

In brief

* The study is evaluating the safety and tolerability of Nivolumab (BMS-936558) when combined with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine; Cisplatin/Pemetrexed; and Carboplatin/Paclitaxel) in subjects with NSCLC. * The study is evaluating the safety and tolerability of Nivolumab as maintenance therapy in combination with Bevacizumab/Avastin that will be given after at least 4 cycles of platinum doublet chemotherapy. * The study is evaluating the safety and tolerability of Nivolumab in combination with Erlotinib among epidermal growth factor receptor (EGFR) mutation positive non-squamous NSCLC subjects and as monotherapy in subjects with NSCLC. * The study is evaluating the safety and tolerability of Nivolumab in combination with Ipilimumab in subjects with squamous and non-squamous NSCLC. * The study is evaluating the safety and tolerability of Nivolumab as switch maintenance therapy in subjects with squamous and non-squamous NSCLC. * The study is evaluating the safety and tolerability of Nivolumab as monotherapy among subjects with untreated, asymptomatic brain metastases and no evidence of cerebral edema.

Key facts

Study ID: NCT01454102
Run by: Bristol-Myers Squibb
People needed: 472
Starts: 2011-12-16
Expected to finish: 2021-07-23
Last updated by the study team: 2021-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Newly diagnosed and confirmed Stage IIIB/IV NSCLC
Previously treated NSCLC with asymptomatic brain metastases (eligible for Arm M) See additional details below
Men and women aged ≥18 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Subject must be chemotherapy naive (except Arm D, K, L and M). Prior use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is acceptable. For Arms D, K, and L, subjects must be non-progressors within 42 days after completion of first-line treatment with ≥4 cycles of Platinum Doublet chemotherapy with or without Bevacizumab. See below for Arm M
Either a formalin fixed tissue block or a minimum of 10 slides of tumor sample (archived or fresh) must be available for biomarker evaluation (a local pathologist must review for adequacy of sampling)
Life expectancy of at least 3 months
Prior radiotherapy must have been completed at least 2 weeks prior to study entry
For Arm M:
No more than 4 brain metastases
Each brain metastases ≤3 cm in size
No evidence of cerebral edema
Subjects must be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroids for ≥10 days prior to initiation of study treatment
At least 1 measurable target brain lesion >0.5 cm and no larger than 3 cm in diameter and/or 2 measurable brain target lesions >0.3 cm
No prior radiation therapy, surgery, or other local therapy for target brain lesions
Must have received at least one prior systemic anticancer therapy for NSCLC

You may not qualify if…

Subjects with symptomatic brain metastases, spinal cord compression, or intractable back pain due to a compressive or destructive mass
Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy
Any active or history of a known autoimmune disease
Subjects with previous malignancies (except non-melanoma skin cancers, in situ bladder cancer, gastric, or colon cancers or cervical cancers/dysplasia, or breast carcinoma in situ) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period
History of Grade ≥2 neuropathy
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity

Where it is running

Ucla — Los Angeles, California, United States
Yale University — New Haven, Connecticut, United States
H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
Memorial Sloan Kettering Nassau — New York, New York, United States
Duke University Medical Center — Durham, North Carolina, United States
Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
Ut Southwestern Medical Center At Dallas — Dallas, Texas, United States
University of Washington - Seattle Cancer Care Alliance — Seattle, Washington, United States
Local Institution — Hamilton, Ontario, Canada
Local Institution — Ottawa, Ontario, Canada
Local Institution — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.